Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: ESAIY )

10.70 +0.10 (+0.94%)
Streaming Delayed Price Updated: 3:53 PM EDT, Aug 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,541
Open 10.56
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 10.60
Today's Range 10.53 - 10.70
52wk Range 8.420 - 16.15
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement
The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer's. Despite this, NICE stated... 
Via Benzinga
Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED
Japan’s Eisai Pharma formed a collaboration with SEED, a Pennsylvania biotech, to develop molecular glues for targeted protein degradation of disease-causing proteins. SEED is eligible to receive up to... 
Via Talk Markets

Performance

YTD
-13.40%
-13.40%
1 Month
+2.66%
+2.66%
3 Month
-0.19%
-0.19%
6 Month
+4.59%
+4.59%
1 Year
-31.19%
-31.19%

More News

Read More
Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
Via Investor's Business Daily
The 3 Best Neuroscience Biotech Stocks to Buy Now
Via InvestorPlace
Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
Via Talk Markets
3 Highly Rated Biotech Stocks for Your July Buy List
Via InvestorPlace
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
Via Benzinga
Exposures Product Safety
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
Via Investor's Business Daily
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
Via Benzinga
Exposures Product Safety
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
Via Investor's Business Daily
Exposures Product Safety
Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
Via Investor's Business Daily
Exposures Product Safety
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
Via Investor's Business Daily
Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline?
Via Investor's Business Daily
Topics Earnings
Exposures Financial
3 Stocks Wall Street Is Ignoring (But You Shouldn’t): April Edition
Via InvestorPlace
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
Via Investor's Business Daily
Exposures Product Safety
3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good
Via InvestorPlace
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
Via Talk Markets
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
Via InvestorPlace
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Via Investor's Business Daily
3 Aging Population Stocks to Profit from the Boomer Generation
Via InvestorPlace
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Via Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Via Investor's Business Daily
3 Biotech Moonshots to Bet on the Future of Health
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
The 3 Best Biotech Stocks to Buy Now: September 2023
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.